ArticleFrontiers in oncology2025

Therapeutic outcomes of enzalutamide-docetaxel combination versus docetaxel monotherapy in post-sequential androgen receptor axis-targeted therapy failure metastatic castration-resistant prostate cancer.

Zhiyu Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.